Vaxart, Inc. financial data

Symbol
VXRT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
170 Harbor Way, Suite 300, South San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Aviragen Therapeutics, Inc. (to 2/15/2018), Biota Pharmaceuticals, Inc. (to 4/13/2016), NABI BIOPHARMACEUTICALS (to 11/8/2012), NABI BIOPHARMACEUTICALS (to 6/29/2010), NABI /DE/ (to 2/14/2002), NORTH AMERICAN BIOLOGICALS INC (to 2/14/1996)
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 412 % -32.3%
Debt-to-equity 51.4 % +36.9%
Return On Equity -121 % -30.8%
Return On Assets -80 % -18.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 174 M shares +28.3%
Common Stock, Shares, Outstanding 177 M shares +30.2%
Entity Public Float 110 M USD -72%
Common Stock, Value, Issued 18 K USD +28.6%
Weighted Average Number of Shares Outstanding, Basic 169 M shares +24.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.18 M USD +223%
Research and Development Expense 67.5 M USD -18.1%
General and Administrative Expense 23.2 M USD -21%
Operating Income (Loss) -81.8 M USD +29.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -81.5 M USD +24.4%
Income Tax Expense (Benefit) 277 K USD +264%
Net Income (Loss) Attributable to Parent -81.7 M USD +24.2%
Earnings Per Share, Basic -0.52 USD/shares +37.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26.7 M USD -42.9%
Cash, Cash Equivalents, and Short-term Investments 36.7 M USD -48.9%
Accounts Receivable, after Allowance for Credit Loss, Current 556 K USD +111%
Other Assets, Current 2.11 M USD
Assets, Current 44.3 M USD -41.6%
Property, Plant and Equipment, Net 11.1 M USD -22.8%
Operating Lease, Right-of-Use Asset 23.8 M USD -14.7%
Intangible Assets, Net (Excluding Goodwill) 4.11 M USD -15.1%
Goodwill 4.51 M USD 0%
Other Assets, Noncurrent 917 K USD -62.7%
Assets 88.7 M USD -31.7%
Accounts Payable, Current 3.98 M USD +2.47%
Employee-related Liabilities, Current 3.2 M USD +11.7%
Accrued Liabilities, Current 4.98 M USD -28.6%
Liabilities, Current 14.1 M USD -9.99%
Operating Lease, Liability, Noncurrent 16.7 M USD -12.9%
Other Liabilities, Noncurrent 309 K USD +25.6%
Liabilities 33 M USD -17.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -10 K USD +85.7%
Retained Earnings (Accumulated Deficit) -434 M USD -23.2%
Stockholders' Equity Attributable to Parent 55.7 M USD -38%
Liabilities and Equity 88.7 M USD -31.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.2 M USD +13.4%
Net Cash Provided by (Used in) Financing Activities 18.2 M USD +1181%
Net Cash Provided by (Used in) Investing Activities -5.02 M USD -120%
Common Stock, Shares Authorized 250 M shares 0%
Common Stock, Shares, Issued 177 M shares +30.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.02 M USD -431%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26.7 M USD -44.8%
Deferred Tax Assets, Valuation Allowance 82.5 M USD +24.4%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 90.2 M USD +21.1%
Operating Lease, Liability 19.5 M USD -9.42%
Depreciation 3.8 M USD +50.2%
Payments to Acquire Property, Plant, and Equipment 131 K USD -89.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -81.7 M USD +24.1%
Lessee, Operating Lease, Liability, to be Paid 24.8 M USD -13.9%
Property, Plant and Equipment, Gross 18.8 M USD +1.6%
Operating Lease, Liability, Current 2.8 M USD +19.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.03 M USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.51 M USD +5.52%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.3 M USD -27.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.21 M USD +4.66%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) 0 USD
Current Income Tax Expense (Benefit) 261 K USD +290%
Preferred Stock, Shares Authorized 5 M shares 0%
Unrecognized Tax Benefits 6.57 M USD +32.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.39 M USD +3.54%
Operating Lease, Payments 2 M USD +81.8%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 3 K USD 0%
Current Federal Tax Expense (Benefit) 0 USD
Amortization of Intangible Assets 700 K USD -39.8%
Deferred Tax Assets, Net of Valuation Allowance 7.74 M USD -5.31%
Share-based Payment Arrangement, Expense 15.6 M USD +19.1%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%